US biotech company Advaxis has completed patient recruitment for the phase I/II trial of Lovaxin C, a Listeria-based immunotherapy for cervical cancer.
Subscribe to our email newsletter
The patient enrollment commenced after dosing 15 patients in an escalating dose clinical trial that was conducted in Mexico, Serbia and Israel. The objective of this trial was to establish a range of safe doses up to a maximally tolerated dose, which has been achieved.
Advaxis plans to complete patient reporting in July, report the results over the following 2 months, and submit an IND for Lovaxin C to the FDA by October, 2007. If the IND is approved, it would be followed by additional phase II clinical trials in the US and internationally.
New Jersey-based Advaxis is developing therapeutic cancer vaccines that enhance the immune system’s cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (innate and classical immunity) to develop safer and more effective Listeria based cancer vaccines.